Albendazole is a broad-spectrum anthelmintic. Animals and human studies have shown that albendazole exhibits vermicidal, ovicidal and larvicidal activity. The drug is thought to exert its anthelmintic effect by blocking glucose uptake in the susceptible helminthes, thereby depleting the energy level until it becomes inadequate for survival. These events may be a consequence of the binding and subsequent inhibition of parasite tubulin polymerization by albendazole and its metabolites, although the drug also binds to human tubulin
Albendazole is indicated for use on the following
- Hookworm (Ancyclostoma, Necator)
- Roundworm (Ascaris)
- Threadworm (Enterobius)
- Whipworm (Trichuris)
- Tapeworm (Taenia spp)
- Hydatid disease (Echinococcus)
Albendazole may create nausea/vomiting, epigastric distress, dizziness, pruritis, dry mouth, diarrhea, leucopenia, agranulocytosis, hypospermia.
Hepatorenal impairment, bone marrow depression. Administer within 7 days of the normal menstrual cycle in women of childbearing age. Adequate non-hormonal contraceptive measures must be taken during and for 1 month following the treatment. LFT and blood counts every two months following high dose therapy.
Adult: 400mg as s ingle dose in strongyloidiasis; 400mg once daily for 3 consecutive days
Hydatid disease: 400mg twice daily with meals for 28 days. The therapy may be repeated after 14 days intervals for a total of 3 cycles
Children: 1-2 years: 200mg as a single dose
Above 2 years: the same as adult dose
Store below 30°c in a dry & dark place. Keep out of reach of children.